Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.11.24 | Pharmadrug Inc (2): Pharmadrug issues debenture units to replace debentures | 11 | Stockwatch | ||
15.11.24 | PharmaDrug Inc.: PharmaDrug Announces Issuance of Debenture Units | 741 | Newsfile | Toronto, Ontario--(Newsfile Corp. - November 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
PHARMADRUG Aktie jetzt für 0€ handeln | |||||
31.10.24 | Pharmadrug Inc (2): Pharmadrug to issue $414,523 in debenture units | 1 | Stockwatch | ||
31.10.24 | PharmaDrug Inc.: PharmaDrug Announces Proposed Issuance of Debenture Units | 409 | Newsfile | Toronto, Ontario--(Newsfile Corp. - October 31, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
31.10.24 | Pharmadrug Inc (2): Pharmadrug completes PD-001 stability study | 2 | Stockwatch | ||
31.10.24 | PharmaDrug Inc.: PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases | 261 | Newsfile | Toronto, Ontario--(Newsfile Corp. - October 31, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
20.09.24 | PharmaDrug Subsidiary Begins Prep Work For Clinical Trial Of PD-001 For Viral Infectious Diseases | 4 | The Deep Dive | ||
19.09.24 | Pharmather Holdings Ltd: Pharmadrug begins start-up work for PD-001 study | 2 | Stockwatch | ||
19.09.24 | Pharmadrug Inc (2): Pharmadrug begins start-up work for PD-001 study | 2 | Stockwatch | ||
19.09.24 | PharmaDrug Inc.: PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases | 275 | Newsfile | Toronto, Ontario--(Newsfile Corp. - September 19, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research,... ► Artikel lesen | |
28.08.24 | Pharmadrug Inc (2): Pharmadrug details plans for cepharanthine development | 2 | Stockwatch | ||
28.08.24 | Pharmather Holdings Ltd: Pharmadrug details plans for cepharanthine development | 3 | Stockwatch | ||
28.08.24 | PharmaDrug Subsidiary To Focus Development Of PD-001 On Viral Infectious Diseases | 1 | The Deep Dive | ||
28.08.24 | PharmaDrug Inc.: PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases | 434 | Newsfile | Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
21.08.24 | PharmaDrug Inc.: PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins | 483 | Newsfile | Toronto, Ontario--(Newsfile Corp. - August 21, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
19.08.24 | PharmaDrug Inc.: PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine | 452 | Newsfile | Toronto, Ontario--(Newsfile Corp. - August 19, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
23.05.24 | PharmaDrug Inc.: Pharmadrug's Securedose Announces LOI with Canadian Controlled Drug Substance Licensed Dealer for Patent Pending Pharmaceutical Grade Cocaine | 322 | Newsfile | Toronto, Ontario--(Newsfile Corp. - May 23, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
15.05.24 | PharmaDrug Inc.: PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine | 264 | Newsfile | Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
13.05.24 | PharmaDrug Inc.: PharmaDrug Provides Forward Plan to Move Its Patent Pending Process and Formulation of Pharmaceutical Grade Biosynthetic Cocaine Through Development into Commercialization | 326 | Newsfile | Toronto, Ontario--(Newsfile Corp. - May 13, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
02.05.24 | PharmaDrug Inc.: PharmaDrug Announces Director Appointment and Resignation | 752 | Newsfile | Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
AURORA CANNABIS | 5,635 | +0,36 % | Aurora Cannabis Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
CANOPY GROWTH | 1,566 | +0,77 % | Canopy Growth: Buffett steigt (indirekt) ein | Aus den jüngsten 13F-Berichten geht hervor, dass Warren Buffett beim größten Wein-Produzenten der Welt, Constellation Brands, eingestiegen ist. Damit geht Buffett auch ein - höchstwahrscheinlich ungewolltes... ► Artikel lesen | |
TILRAY BRANDS | 0,900 | +2,65 % | Tilray Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
INNOCAN PHARMA | 0,151 | +0,67 % | Innocan Pharma erhält für seine liposomale CBD-Injektion das erste Patent in Indien | Innovative Therapie bei chronischen Schmerzen erhält Schutz des geistigen Eigentums auf Indiens 55-Milliarden-Dollar-schwerem
Pharmamarkt
Herzliya, Israel und Calgary, Alberta -... ► Artikel lesen | |
TAAT GLOBAL ALTERNATIVES | 0,157 | 0,00 % | TAAT Global Alternatives Inc (2): TAAT Global closes acquisition of Premium Products | ||
DERMAPHARM | 39,350 | +1,42 % | Dermapharm: Aktie wird abgestuft | 2024 ist für Dermapharm gut verlaufen. Die Analysten von mwb research gehen davon aus, dass die Gesellschaft ihre Jahresprognose schaffen wird. Dermapharm rechnet mit einem Umsatz von 1,17 Milliarden... ► Artikel lesen | |
CRONOS GROUP | 1,836 | -2,29 % | Cronos-Aktie: Lohnt sich hier ein Kauf? | Die Aktie von Cronos ist wie die meisten Cannabiswerte in den vergangenen Monaten unter Druck geraten. Doch ist der kanadische Titel jetzt einen Blick für Anleger wert? Immerhin winken hier vergleichsweise... ► Artikel lesen | |
SYNBIOTIC | 3,820 | +1,60 % | SYNBIOTIC plant weitere Übernahmen in 2025 | Mitteilung der SYNBIOTIC SE: SYNBIOTIC mit vier neuen Beteiligungen in 2024: Weitere Übernahmen für 2025 in Sicht Die europäische Industriehanf- und Cannabis-Unternehmensgruppe SYNBIOTIC SE (ISIN DE000A3E5A59... ► Artikel lesen | |
VIATRIS | 10,795 | +0,33 % | Viatris: Uniting Against AMR: Global Solutions Need Local and Global Collaboration | NORTHAMPTON, MA / ACCESS Newswire / February 19, 2025 / By: James Headen Pfitzer, Senior Director, Global Policy, Corporate Affairs, Viatris and Melissa Mitchell, AMR IA Secretariat LeadOur world is... ► Artikel lesen | |
DIGICANN VENTURES | 0,004 | 0,00 % | CSE Bulletin: Halted for Fundamental Change - Digicann Ventures Inc. (DCNN) | le 30 septembre/September 2024
Trading in the shares of Digicann Ventures Inc. will remain halted pending receipt and review of acceptable documentation regarding the Fundamental Change pursuant... ► Artikel lesen | |
ORGANIGRAM | 1,168 | -6,41 % | Organigram Reports First Quarter Fiscal 2025 Results | TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its results for the first quarter... ► Artikel lesen | |
CRESCO LABS | 0,863 | +0,76 % | Cresco Labs Demonstrates Success of Cash Flow Focused Strategy with Third Quarter 2024 Financial Results | Record quarterly operating cash flow of $49 million and year to date operating cashflow of $103 million, an increase of 66% from the prior year period
Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF)... ► Artikel lesen | |
GREEN THUMB INDUSTRIES | 6,725 | -1,61 % | Multi-Bagger entdeckt!: Der europäische Cannabissektor wird in den nächsten Jahren auf 24 Mrd. $ explodieren - diese Aktie profitiert! | ||
SNDL | 1,677 | -0,59 % | HYTN und SNDL streben Zusammenarbeit bei der Entwicklung von GMP-konformen Vape-Kartuschen für globale Märkte an | Vancouver, British Columbia - 21. Januar 2025 / IRW-Press / HYTN Innovations Inc. (CSE: HYTN, FWB: 85W0, OTC PINK: HYTNF) ("HYTN" oder das "Unternehmen"), ein Unternehmen, das sich auf die Herstellung... ► Artikel lesen | |
MYDECINE INNOVATIONS GROUP | 0,004 | -12,50 % | Mydecine Innovations Group Inc - Mydecine Announces Filing of Q3 Financial Statements | Mydecine Innovations Group Inc - Mydecine Announces Filing of Q3 Financial Statements
PR Newswire
LONDON, United Kingdom, November 21
MYDECINE ANNOUNCES FILING OF Q3 FINANCIAL... ► Artikel lesen |